Ⅱ型糖尿病新药? 楼主,个人认为ddp-4抑制剂是个热点,2型糖尿病的其它靶标也是研究热点 如,aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a ppar modulator ) with affinity to pparα and pparγ, which is being developed by hoffmann–la roche for the treatment of type ii diabetes. it is currently in phase ii clinical trials.,随便问下你们有没有把saxagliptin的中间体合成搞定了?查看更多